Acute inactivation of mTor in vitro also highlights the differential requirement of mTor function in proliferating and transformed cells.
Our data constitute a strong rationale for developing specific mTOR inhibitors targeting both mTORC1 and mTORC2 for the treatment of tumors triggered by PTEN deficiency and aberrant mTOR signaling.